Greg Gianforte bought Novartis AG ADR (NYSE: NVS)
Greg Gianforte (R-MT), a U.S. Representative, has disclosed 1 trade in Novartis AG ADR (NVS) since 2020, a single purchase, worth an estimated $8K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a purchase: Greg Gianforte bought $1,001 - $15,000 of Novartis AG ADR (NYSE: NVS) on March 18, 2020. Since that trade, NVS is up +165.76% against the S&P 500 up +232.60%, an outperformance of -66.84%.
Data updated
Greg Gianforte's NVS trades vs the price
NVS is up +165.76% since Greg Gianforte bought on March 18, 2020, versus +232.60% for the S&P 500.
Performance since this trade
All Greg Gianforte NVS trades
Greg Gianforte & NVS trading FAQ
Is it legal for Greg Gianforte to trade Novartis AG ADR (NVS) stock?
Yes. Members of Congress are allowed to trade individual stocks, including Novartis AG ADR (NVS), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did Greg Gianforte buy NVS?
Greg Gianforte disclosed a purchase of $1,001 - $15,000 of Novartis AG ADR (NVS) on March 18, 2020, according to public STOCK Act filings.
How has NVS performed since Greg Gianforte's trade?
Since Greg Gianforte bought NVS on March 18, 2020, the stock is up +165.76%, versus +232.60% for the S&P 500 over the same period, an outperformance of -66.84%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional NVS trades?
Quantellect tracks every disclosed congressional trade in Novartis AG ADR (NVS) on the Novartis AG ADR congressional trading page, which aggregates filings across all members of Congress.
Greg Gianforte's NVS tradesAll congressional filings for Novartis AG ADRGreg Gianforte's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.